Welcome to the ARLG Newsletter! Here, you will receive important updates from ARLG regarding recent events, grants, publications, and the committees that help us work toward our mission: to prioritize, design, and execute clinical research that will impact the prevention, diagnosis, and treatment of infections caused by antibiotic-resistant bacteria.

Get Involved with ARLG

ARLG continuously accepts proposals for clinical studies designed to prevent, diagnose, treat, or eradicate antibiotic-resistant bacterial pathogens. We also award grants and fellowships to qualified investigators. If you are interested in getting involved with ARLG, apply now or contact us for more information.

Vance Fowler Delivers Finland Award Lecture on S. Aureus, Career Lessons, and the Importance of Mentors

In October, ARLG co-principal investigator Vance Fowler shared insight from his two decades studying Staphylococcus aureus as part of an IDWeek 2020 lecture titled “Staphylococcus aureus: Lessons Learned from 20 Years with the Persistent Pathogen.” The Finland lecture is awarded each year to someone who has made key contributions in the areas of bacterial pathogenesis, antimicrobial agents, emerging infections, and hospital-acquired infections.

Dr. Fowler began the lecture by discussing his first major lesson: “plans change.” While in residency, he thought his career would be dedicated to studying malaria in East Africa but his mentor, Ralph Corey, MD, suggested he study S. aureus instead. During his residency, he started the S. aureus Bacteremia Group...
In Remembrance of John Bartlett

We are deeply saddened to share news of the passing of our mentor, colleague, and friend John Bartlett, M.D. on Jan. 19. In addition to the many significant contributions that helped build the ARLG, John designed and led the ARLG mentoring committee in the initial years of the grant. To date, the ARLG mentor program has provided mentorship and career-development opportunities to more than 45 mentees and has achieved John’s vision to train the next generation of clinician scientists in antibacterial resistance.

While his early work focused on Clostridium difficile, John had a profound impact on many areas of infectious diseases including HIV/AIDS, bioterrorism, antibacterial resistance, pneumonia, diagnostics, and mentoring. A giant in the field, John’s legacy and the impact of his work will continue to benefit others for years to come.

We extend our heartfelt condolences to John’s family and many friends. Those wishing to make a memorial contribution in honor of Dr. Bartlett can donate a tribute gift to the IDSA Foundation which will be recognized in the IDSA Jean and John G. Bartlett Member Lounge in Arlington, Virginia.

Yohei Doi Promoted to Professor of Medicine

We congratulate Yohei Doi, MD, PhD, on his promotion to Professor of Medicine at the University of Pittsburgh! Dr. Doi is the chair for ARLG’s Gram-Negative Committee which advances research and improves patient outcomes by designing clinical trials for gram-negative infections and mentoring ARLG junior investigators.

Dr. Doi also serves as the Director of the Center for
Innovative Antimicrobial Therapy (CIAT) at the University of Pittsburgh as well as the Professor and Chair of Microbiology at Fujita Health University in Aichi, Japan.

Yohei Doi, MD, PhD

ECCMID 2021 and Upcoming Abstract Deadline

The European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) will be here before you know it! From July 9 – 12, clinical microbiology and international infectious diseases experts will present their latest findings and information. The event will take place in Vienna, Austria and online.

Share your research or case report by submitting your abstract no later than February 24, 2021. Get more information about the guidelines and register for the event.

Register to Attend
Submit Your Abstract

The American Society for Microbiology (ASM) and the Federation for European Microbiological Societies (FEMS) have teamed up to bring you the World Microbe Forum happening online June 20 – 24.

Experts from around the world will offer insight and discuss solutions on topics such as infectious pathogens, agriculture and food microbiology, and the role of microbes in...
Two New FDA ORISE Fellowships

Just announced! The Food and Drug Association (FDA) is offering two fellowship opportunities through the Oak Ridge Institute for Science and Education (ORISE).

- **FDA Antibacterial Drug Resistance desirability of outcome ranking (DOOR) Fellowship** will evaluate ordinal endpoints using the DOOR approach for anti-infective clinical trials for indications such as hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP), complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI) and acute bacterial skin and skin structure infections (ABSSSI). DOOR is an innovative approach in clinical trials to evaluate the global benefits and risks of an intervention.

- **FDA Antibacterial Drug Resistance complicated urinary tract infection (cUTI) Fellowship** will review data from recent cUTI clinical trials to assess the degree of discordance between the clinical and microbiologic endpoints and the reasons for the discordance. Based on the data, consideration will be given to revising the endpoint if needed.

Both fellowships are one-year opportunities and will begin June 2021.

You’re vaccinated. What’s next?

A national vaccine safety-surveillance study called HERO-TOGETHER invites healthcare workers who received their first or second vaccine to join. Healthcare workers will complete brief surveys over two years to share safety information. By collecting different people’s experiences with the vaccine we can better understand
Recent Publications

View the following recent ARLG publications.


Coming soon!
Chambers HF, Evans SR, Patel R, Cross HR, Harris AD, Doi Y, Boucher HW, van Duin D,